A molecular jewel for hemophilia A treatment

Research output: Contribution to journalReview articlepeer-review

Standard

A molecular jewel for hemophilia A treatment. / Rayes, Julie; Lacroix-Desmazes, Sébastien.

In: Blood, Vol. 135, No. 17, 23.04.2020, p. 1417-1419.

Research output: Contribution to journalReview articlepeer-review

Harvard

Rayes, J & Lacroix-Desmazes, S 2020, 'A molecular jewel for hemophilia A treatment', Blood, vol. 135, no. 17, pp. 1417-1419. https://doi.org/10.1182/BLOOD.2020005250

APA

Vancouver

Author

Rayes, Julie ; Lacroix-Desmazes, Sébastien. / A molecular jewel for hemophilia A treatment. In: Blood. 2020 ; Vol. 135, No. 17. pp. 1417-1419.

Bibtex

@article{8c5024b2cfbf43c1993d0721a23b6061,
title = "A molecular jewel for hemophilia A treatment",
abstract = "In this issue of Blood, Seth Chhabra et al describe the engineering of a new therapeutic chimera composed of B domain-deleted (BDD) factor VIII (FVIII), FVIII-binding domain of von Willebrand factor (VWF), Fcg1 fragment, and XTEN polypeptides.1 The molecule, referred to as rFVIIIFc-VWF-XTEN or BIVV001, has a prolonged half-life that is independent from endogenous VWF and is hemostatically competent.",
author = "Julie Rayes and S{\'e}bastien Lacroix-Desmazes",
note = "Funding Information: Conflict-of-interest disclosure: J.R. declares no competing financial interests. S.L.-D. is the recipient of a research grant from Sanofi Genzyme and Sobi. n Publisher Copyright: {\textcopyright} 2020 by The American Society of Hematology. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = apr,
day = "23",
doi = "10.1182/BLOOD.2020005250",
language = "English",
volume = "135",
pages = "1417--1419",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "17",

}

RIS

TY - JOUR

T1 - A molecular jewel for hemophilia A treatment

AU - Rayes, Julie

AU - Lacroix-Desmazes, Sébastien

N1 - Funding Information: Conflict-of-interest disclosure: J.R. declares no competing financial interests. S.L.-D. is the recipient of a research grant from Sanofi Genzyme and Sobi. n Publisher Copyright: © 2020 by The American Society of Hematology. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/4/23

Y1 - 2020/4/23

N2 - In this issue of Blood, Seth Chhabra et al describe the engineering of a new therapeutic chimera composed of B domain-deleted (BDD) factor VIII (FVIII), FVIII-binding domain of von Willebrand factor (VWF), Fcg1 fragment, and XTEN polypeptides.1 The molecule, referred to as rFVIIIFc-VWF-XTEN or BIVV001, has a prolonged half-life that is independent from endogenous VWF and is hemostatically competent.

AB - In this issue of Blood, Seth Chhabra et al describe the engineering of a new therapeutic chimera composed of B domain-deleted (BDD) factor VIII (FVIII), FVIII-binding domain of von Willebrand factor (VWF), Fcg1 fragment, and XTEN polypeptides.1 The molecule, referred to as rFVIIIFc-VWF-XTEN or BIVV001, has a prolonged half-life that is independent from endogenous VWF and is hemostatically competent.

UR - http://www.scopus.com/inward/record.url?scp=85084999833&partnerID=8YFLogxK

U2 - 10.1182/BLOOD.2020005250

DO - 10.1182/BLOOD.2020005250

M3 - Review article

C2 - 32324867

AN - SCOPUS:85084999833

VL - 135

SP - 1417

EP - 1419

JO - Blood

JF - Blood

SN - 0006-4971

IS - 17

ER -